Posted by Michael Wonder on 01 Dec 2016
GSK gets green light to sell breakthrough asthma treatment to the NHS
1 December 2016 - GlaxoSmithKline has had one of its most promising new asthma drugs recommended for use on the NHS in England and Wales after agreeing to cut the price of the treatment.
The National Institute for Health and Care Excellence has said mepolizumab, sold under the brand name Nucala, should be available to patients through the NHS who suffer from a severe type of asthma.
Nucala is a new class of asthma drug called a biologic, which targets special white blood cells that cause inflammation and breathing difficulties in many people with asthma.
